Movement Alert｜Moderna, Inc. Falls 4.26% in Pre-Market Trading, Melanoma Vaccine Data Leak Aftermath Continues to Weigh on Sentiment

Market Focus10-26 16:00

On October 26, Moderna, Inc. fell 4.26% in Pre-Market Trading, trading at $192.73 per share, with turnover of $878.6 thousand.

The move came as the market continued to digest the fallout from leaked phase 3 data tied to Moderna, Inc. and Merck's personalized melanoma vaccine, which has kept sentiment under pressure.

Circulating details indicated the therapy reduced recurrence risk by 42% and distant metastasis risk by 38%, below earlier trial figures of 49% and 59%. That gap has raised concern that the eventual full release may be less likely to deliver a major upside surprise. Options positioning has also turned more cautious, with longer-dated bull call spreads clustered around $210 to $222.5, while out-of-the-money $260 calls were reportedly sold for income, suggesting a more restrained view on near-term upside.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment